Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma

Genome Research

Volumn 24, Issue 9, 2014, Pages 1411-1420

  Yoshida, Aki ^d   Totoki, Yasushi ^a   Yoshida, Akihiko ^b   Hosoda, Fumie ^a   Nakamura, Hiromi ^a   Hama, Natsuko ^a   Ogura, Koichi ^c   Fujiwara, Tomohiro ^c   Arai, Yasuhito ^a   Toguchida, Junya ^e   Tsuda, Hitoshi ^b   Miyano, Satoru ^f   Kawai, Akira ^c   Shibata, Tatsuhiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b Division of Pathology and Clinical Laboratories   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; ISOCITRATE DEHYDROGENASE 1; ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR TYPE II-A; COL2A1 PROTEIN, HUMAN; FIBRONECTIN; FN1 PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; TRANSCRIPTOME;

ACVR2A GENE; ADOLESCENT; ADULT; AGED; ARTICLE; CARTILAGE TUMOR; CHONDROGENESIS; CHONDROMATOSIS; CHONDROSARCOMA; CHROMOSOME 5; CLINICAL ARTICLE; COL2A1 GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; ENCHONDROMA; EPIGENETICS; EXON; EXTRACELLULAR MATRIX; FEMALE; FN1 ACVR2A GENE; FUSION GENE; GENE EXPRESSION; GENE FUSION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; HUMAN GENOME; HUMAN TISSUE; INDEL MUTATION; ISOCITRATE DEHYDROGENASE 1 GENE; MALE; MIDDLE AGED; MUSCLE TISSUE; MUTATION RATE; NONSENSE MUTATION; ONCOGENE; OSTEOCHONDROMA; POINT MUTATION; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SOMATIC MUTATION; STOP CODON; TERT GENE; VERY ELDERLY; WHOLE GENOME SEQUENCING; YEATS2 GENE; GENETICS; METABOLISM; MUTATION;

ACTIVIN RECEPTORS, TYPE II; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHONDROSARCOMA; COLLAGEN TYPE II; FEMALE; FIBRONECTINS; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; OSTEOCHONDROMATOSIS; TRANSCRIPTOME;

EID: 84907206926     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.160598.113     Document Type: Article

References (44)

1. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, et al. 2011a. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224: 334-343.
2. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, McCarthy S, Fantin VR, Straley KS, Lobo S, et al. 2011b. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 43: 1262-1265.
3. Asp J, Inerot S, Block JA, Lindahl A. 2001. Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma. J Orthop Res 19: 149-154.
4. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, et al. 2011. The genomic complexity of primary human prostate cancer. Nature 470: 214-220.
5. Bovée JV, Hogendoorn PC, Wunder JS, Alman BA. 2010. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 10: 481-488.
6. Bowen ME, Boyden ED, Holm IA, Campos-Xavier B, Bonafé L, Superti- Furga A, Ikegawa S, Cormier-Daire V, Bovée JV, Pansuriya TC, et al. 2011. Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome. PLoS Genet 7: e1002050.
7. Briggs TA, Rice GI, Daly S, Urquhart J, Gornall H, Bader-Meunier B, Baskar K, Baskar S, Baudouin V, Beresford MW, et al. 2011. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet 43: 127-131.
8. Cheah KS, Stoker NG, Griffin JR, Grosveld FG, Solomon E. 1985. Identification and characterization of the human type II collagen gene (COL2A1). Proc Natl Acad Sci 82: 2555-2559.
9. Donaldson CJ, Mathews LS, ValeWW. 1992. Molecular cloning and binding properties of the human type II activin receptor. Biochem Biophys Res Commun 184: 310-316.
10. Esapa CT, Hough TA, Testori S, Head RA, Crane EA, Chan CP, Evans H, Bassett JH, Tylzanowski P, McNally EG, et al. 2012. A mouse model for spondyloepiphyseal dysplasia congenita with secondary osteoarthritis due to a Col2a1 mutation. J Bone Miner Res 27: 413-428.
11. Fletcher CDM, Unni K, Mertens F. 2002. Pathology and genetics of tumours of soft tissues and bone. IARC Press, Lyon, France.
12. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al. 2011. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: D945-D950.
13. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, et al. 2012. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44: 760-764.
14. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, et al. 2012. Genomic landscape of nonsmall cell lung cancer in smokers and never-smokers. Cell 150: 1121-1134.
15. Harrison CA, Gray PC, Vale WW, Robertson DM. 2005. Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 16: 73-78.
16. Hecht JT, Hogue D, Wang Y, Blanton SH, Wagner M, Strong LC, RaskindW, Hansen MF, Wells D. 1997. Hereditary multiple exostoses (EXT): mutational studies of familial EXT1 cases and EXT-associated malignancies. Am J Hum Genet 60: 80-86.
17. Hong C, Moorefield KS, Jun P, Aldape KD, Kharbanda S, Phillips HS, Costello JF. 2007. Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. Proc Natl Acad Sci 104: 10974-10979.
18. Hopyan S, Gokgoz N, Poon R, Gensure RC, Yu C, Cole WG, Bell RS, Jüppner H, Andrulis IL, Wunder JS, et al. 2002. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet 30: 306-310.
19. Hsing AW, Chokkalingam AP. 2006. Prostate cancer epidemiology. Front Biosci 11: 1388-1413.
20. Koziel L, Kunath M, Kelly OG, Vortkamp A. 2004. Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Dev Cell 6: 801-813.
21. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ, Marra MA. 2009. Circos: an information aesthetic for comparative genomics. Genome Res 19: 1639-1645.
22. Larramendy ML, Tarkkanen M, Valle J, Kivioja AH, Ervasti H, Karaharju E, Salmivalli T, Elomaa I, Knuutila S. 1997. Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. Am J Pathol 150: 685-691.
23. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows- Wheeler transform. Bioinformatics 25: 1754-1760.
24. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Matth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The sequence alignment/map format and SAMtools. Bioinformatics 25: 2078-2079.
25. Matzuk MM, Kumar TR, Bradley A. 1995. Different phenotypes for mice deficient in either activins or activin receptor type II. Nature 374: 356-360.
26. Moniz S, Veríssimo F, Matos P, Brazão R, Silva E, Kotelevets L, Chastre E, Gespach C, Jordan P. 2007. Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2. Oncogene 26: 6071-6081.
27. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, et al. 2012. Mutational processes molding the genomes of 21 breast cancers. Cell 149: 979-993.
28. Nishimura G, Haga N, Kitoh H, Tanaka Y, Sonoda T, Kitamura M, Shirahama S, Itoh T, Nakashima E, Ohashi H, et al. 2005. The phenotypic spectrum of COL2A1 mutations. Hum Mutat 26: 36-43.
29. Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, Cleton-Jansen AM, van Oosterwijk JG, Verbeke SL, Meijer D, et al. 2011. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 43: 1256-1261.
30. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, et al. 2010a. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463: 184-190.
31. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordóñez GR, Bignell GR, et al. 2010b. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463: 191-196.
32. Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, Escaramis G, Jares P, Beá S, González-Díaz M, et al. 2011. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475: 101-105.
33. Ren H, Tan ZP, Zhu X, Crosby K, Haack H, Ren JM, Beausoleil S, Moritz A, Innocenti G, Rush J, et al. 2012. Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. Cancer Res 72: 3312-3323.
34. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, et al. 2013. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340: 626-630.
35. Schrage YM, Briaire-de Bruijn IH, deMiranda NF, van Oosterwijk J, Taminiau AH, van Wezel T, Hogendoorn PC, Bovée JV. 2009. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 69: 6216-6222.
36. Spranger J, Winterpacht A, Zabel B. 1994. The type II collagenopathies: a spectrum of chondrodysplasias. Eur J Pediatr 153: 56-65.
37. StrattonMR, Campbell PJ, Futreal PA. 2009. The cancer genome. Nature 458: 719-724.
38. Tarpey PS, Behjati S, Cooke SL, Loo PV, Wedge DC, Pillay N, Marshall J, Meara SO, Davies H, Zainal SN, et al. 2013. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet 45: 923-926.
39. Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishikawa S, Tsutsumi S, Sonoda K, Totsuka H, Shirakihara T, et al. 2011. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 43: 464-469.
40. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, et al. 2012. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: 479-483.
41. Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS, Yamamuro T. 1993. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 68: 1134-1139.
42. Wang YL, Faiola F, Xu M, Pan S, Martinez E. 2008. Human ATAC Is a GCN5/ PCAF-containing acetylase complex with a novel NC2-like histone fold module that interacts with the TATA-binding protein. J Biol Chem 283: 33808-33815.
43. Whelan J, McTiernan A, Cooper N, Wong YK, Francis M, Vernon S, Strauss SJ. 2012. Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer 131: E508-E517.
44. Wuyts W, Van Hul W, De Boulle K, Hendrickx J, Bakker E, Vanhoenacker F, Mollica F, Lüdecke HJ, Sayli BS, Pazzaglia UE, et al. 1998. Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses. Am J Hum Genet 62: 346-354.